NRXS Stock Catalyst: Neuraxis, Inc. Receives FDA 510(K) Clearance for IB-Stim

Neuraxis, Inc. (NRXS) announced it has received FDA 510(K) clearance for its IB-Stim device. The clearance is for the treatment of pediatric functional abdominal pain (FAP) associated with functional dyspepsia, and functional dyspepsia (FD) related nausea symptoms.

The IB-Stim device is now cleared to address these specific pediatric conditions, expanding its therapeutic applications. Neuraxis, Inc. has 7,430,800 shares in free float.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.